Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADXN Addex Therapeutics Ltd

Closed 10-08 16:00:00 EDT

3.18

+0.05

+1.60%

盘后3.18

+0.000.00%

16:04 EDT

High3.23	Low3.00	Vol11.68K
Open3.22	D1 Closing3.13	Amplitude7.35%
Mkt Cap5.57M	Tradable Cap4.98M	Total Shares1.75M
T/O36.61K	T/O Rate0.75%	Tradable Shares1.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADXN","market":"US","secType":"STK","nameCN":"Addex Therapeutics Ltd","latestPrice":3.18,"timestamp":1791489600000,"preClose":3.13,"halted":0,"volume":11678,"hourTrading":{"tag":"盘后","latestPrice":3.18,"preClose":3.18,"latestTime":"16:04 EDT","volume":2,"amount":6.21,"timestamp":1791489843427,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.015974440894568776,"floatShares":1567000,"shares":1752435,"eps":-8.664,"marketStatus":"Closed","change":0.05,"latestTime":"10-08 16:00:00 EDT","open":3.22,"high":3.23,"low":3,"amount":36608,"amplitude":0.073482,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.664,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":5,"adr":0,"adrRate":120,"exchange":"NASDAQ","adjPreClose":3.13,"preHourTrading":{"tag":"盘前","latestPrice":3.2731,"preClose":3.13,"latestTime":"09:26 EDT","volume":1135,"amount":3567.60918,"timestamp":1791466003462,"change":0.1431,"changeRate":0.045719,"amplitude":0.118211},"postHourTrading":{"tag":"盘后","latestPrice":3.18,"preClose":3.18,"latestTime":"16:04 EDT","volume":2,"amount":6.21,"timestamp":1791489843427,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.562316},"requestUrl":"/m/hq/s/ADXN","defaultTab":"news","newsList":[{"id":"2673028595","title":"Press Release: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673028595","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673028595?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:00","pubTimestamp":1791435600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","PAM","BK4563","NTX","CSF","BK4081","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672079179","title":"Press Release: Addex Therapeutics Announces Executive Management Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672079179","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672079179?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:00","pubTimestamp":1790917200,"startTime":"0","endTime":"0","summary":"-- Jean-Philippe Rocher Appointed Head of Pharmaceutical Development","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256431","title":"NASDAQ Trade Halt Volatility Trading Pause at 11:24 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256431","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256431?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:24","pubTimestamp":1790609080,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 11:24 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nAQN2ML8OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670528572","title":"Press Release: Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2670528572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670528572?lang=en_us&edition=fundamental","pubTime":"2026-09-28 13:00","pubTimestamp":1790571600,"startTime":"0","endTime":"0","summary":"-- Regained rights to GABAB positive allosteric modulator portfolio from. -- Spin-out company, Neurosterix continued to progress through Phase 1. clinical development with the M4 PAM candidate, NTX-253. -- Continued advancing GABAB PAM chronic cough candidate through preclinical. developmentKey H1 2026 Financial DataCHF' thousands             Q2 26    Q2 25   Change    H1 26    H1 25   Change","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADXN","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669445945","title":"Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669445945","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669445945?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:00","pubTimestamp":1790226000,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, September 24, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST  on September 28, 2026.Title:  Addex Therapeutics Reports 2026 Half-Year and Second Quarter Financial Results and Provides Corporate UpdateDate: September 28, 2026Time: 16:00 CET Joining the Conference Call:1. Participants are required to register in advance of the conference using. the link provided below. Upon registering, each participant will be. provided with Participant Dial-in numbers, and a unique Personal PIN.use the conference acces","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762406","title":"Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762406","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762406?lang=en_us&edition=fundamental","pubTime":"2026-08-26 13:00","pubTimestamp":1787720400,"startTime":"0","endTime":"0","summary":"Chief Executive Officer       Partner, Halsin Partners","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN","EUFX","CROC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661523114","title":"NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2661523114","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661523114?lang=en_us&edition=fundamental","pubTime":"2026-08-21 02:50","pubTimestamp":1787251831,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 02:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nAQN2MFXNA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649647109","title":"Addex Therapeutics announces publication of new ADX71743 preclinical research","url":"https://stock-news.laohu8.com/highlight/detail?id=2649647109","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649647109?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:15","pubTimestamp":1783502113,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADXN","BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649957215","title":"Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness","url":"https://stock-news.laohu8.com/highlight/detail?id=2649957215","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649957215?lang=en_us&edition=fundamental","pubTime":"2026-07-08 13:00","pubTimestamp":1783486800,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647658440","title":"Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2647658440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647658440?lang=en_us&edition=fundamental","pubTime":"2026-06-30 13:00","pubTimestamp":1782795600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio o","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGM","BK4195","ADXN","BK4229","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646694821","title":"Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2646694821","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646694821?lang=en_us&edition=fundamental","pubTime":"2026-06-25 13:41","pubTimestamp":1782366064,"startTime":"0","endTime":"0","summary":"Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60088935/addex-therapeutics-reports-q1-2026-net-loss-chf-1-71m-versus-chf-1-47m-year-ago-cash-chf-0-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646829973","title":"Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2646829973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646829973?lang=en_us&edition=fundamental","pubTime":"2026-06-25 13:00","pubTimestamp":1782363600,"startTime":"0","endTime":"0","summary":"Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 25, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.\"Our spin-out, Neurosterix, made great progress during the quarter and are on track to complete the Phase 1 study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, in July,\" said Tim Dyer, CEO of Addex. \"We look forward to seeing the data from the study when available later in the summer.\"Operating Highlights:-- Spin-out Neurosterix continued to progress through Phase 1 clinical. developmentKey Q1 2026 Financial DataCHF' thousands                     Q1 26    Q1 25   Change","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645204532","title":"Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645204532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645204532?lang=en_us&edition=fundamental","pubTime":"2026-06-22 13:00","pubTimestamp":1782104400,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, June 22, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST  on June 25, 2026.Title:  Addex Therapeutics Reports Q1 2026 Financial Results and Provides Corporate Update. the link provided below. Upon registering, each participant will be","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4218","HST","ADXN","BK4585","BK4588","BK4007","BK4539","BK4181","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641582192","title":"Press Release: Addex Convenes Annual General Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641582192","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641582192?lang=en_us&edition=fundamental","pubTime":"2026-06-05 13:00","pubTimestamp":1780635600,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, June 5, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva .Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant , is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in sub","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXN","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507099","title":"Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507099","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507099?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:08","pubTimestamp":1777532921,"startTime":"0","endTime":"0","summary":"Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/ADXN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631050385","title":"Press Release: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631050385","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631050385?lang=en_us&edition=fundamental","pubTime":"2026-04-30 13:00","pubTimestamp":1777525200,"startTime":"0","endTime":"0","summary":"-- GABAB PAM chronic cough candidate continued towards clinic after. demonstrating robust anti-tussive activity in multiple disease models. -- Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery. -- Entered option and collaboration agreement with Sinntaxis for exclusive. license to intellectual property covering the use of mGlu5 NAM in brain. -- Regained rights to phase 2 mGlu2 PAM asset, ADX71149. -- Partner, Indivior advanced GABAB PAM substance use disorders program. -- Strategic investment in Stalicla SA, confirming commitment to advancing. Geneva, Switzerland, April 30, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.-- Continued advancing GABAB PAM chronic cough candidate through preclinical. -- Advanced the ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADXN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631595029","title":"Addex Therapeutics announces GABAB PAM candidate data","url":"https://stock-news.laohu8.com/highlight/detail?id=2631595029","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631595029?lang=en_us&edition=fundamental","pubTime":"2026-04-29 17:35","pubTimestamp":1777455353,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator candidate in a b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-gabab-pam-candidate-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-gabab-pam-candidate-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ADXN","BK4539","BK4563","PAM","BK4081","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631550195","title":"Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2631550195","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631550195?lang=en_us&edition=fundamental","pubTime":"2026-04-29 13:00","pubTimestamp":1777438800,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, April 29, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator  candidate in a bleomycin -induced idiopathic pulmonary fibrosis  exacerbated chronic cough model.\"Chronic cough remains a significant unmet medical need, particularly in patients suffering from idiopathic pulmonary fibrosis , where persistent coughing substantially impacts quality of life and worsens disease burden,\" said Tim Dyer, CEO of Addex. \"In studies to date, including non-human primates announced last week, robust antitussive efficacy of the compound is combined with a stable respiratory and systemic safety profile, further supporting the therapeutic promise of our GABAB PAM as a novel and well-tolerated approach for chronic cough management.\". Addex","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAM","BK4007","BK4563","BK4081","BK4139","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629882780","title":"Addex Therapeutics says spin-out company to complete NTX-253 study in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2629882780","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629882780?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:46","pubTimestamp":1776937580,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-says-spin-out-company-to-complete-ntx-253-study-in-q2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-says-spin-out-company-to-complete-ntx-253-study-in-q2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139","NTX","ADXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009484","title":"Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629009484?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, April 23, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator  of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, and pharmacokinetics  across both healthy adult participants and those with stable schizophrenia.The clinical study includes a multi-part, ascending-dose design intended to efficiently characterize NTX-253's clinical profile and support subsequent patient-focused development. The study includes both single ascending dose  and multiple ascending dose  components,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADXN","BK4218","PK","BK4563","BK4081","BK4139","NTX","CSF","PAM","BK4181"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.addextherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1341},{"period":"1month","weight":-0.1425},{"period":"3month","weight":-0.4686},{"period":"6month","weight":-0.5258},{"period":"1year","weight":-0.6394},{"period":"ytd","weight":-0.5946}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.20245},{"month":2,"riseRate":0.285714,"avgChangeRate":0.091856},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.134039},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.057535},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.045257},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.098028},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.006493},{"month":8,"riseRate":0.285714,"avgChangeRate":0.058829},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.127045},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.035529},{"month":11,"riseRate":0,"avgChangeRate":-0.116863},{"month":12,"riseRate":0.5,"avgChangeRate":-0.002424}],"exchange":"NASDAQ","name":"Addex Therapeutics Ltd","nameEN":"Addex Therapeutics Ltd","securityTypeName":"DR","adrRate":"1:120"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Addex Therapeutics Ltd,ADXN,Addex Therapeutics Ltd股票,Addex Therapeutics Ltd股票老虎,Addex Therapeutics Ltd股票老虎国际,Addex Therapeutics Ltd行情,Addex Therapeutics Ltd股票行情,Addex Therapeutics Ltd股价,Addex Therapeutics Ltd股市,Addex Therapeutics Ltd股票价格,Addex Therapeutics Ltd股票交易,Addex Therapeutics Ltd股票购买,Addex Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction